用注射药物满足2型糖尿病治疗中未满足的需求：胰高血糖素样肽-1受体激动剂
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
作者信息
Edelman Steve V
机构信息
Professor of Medicine, University of California San Diego, Veterans Affairs Medical Center, San Diego, California, USA.
出版信息
J Fam Pract. 2017 Oct;66(10 Suppl):S12-S16.
PMID:28991932
Abstract
Since 2005, four new GLP-1RAs (liraglutide, albiglutide, dulaglutide, and lixisenatide) and a once-weekly formulation of exenatide were approved for the treatment of persons with T2DM. Another GLP-1RA, semaglutide, is under review by the FDA, as is exenatide administered via an osmotic mini-pump.
摘要
自2005年以来，四种新型胰高血糖素样肽-1受体激动剂（利拉鲁肽、阿必鲁肽、度拉鲁肽和利司那肽）以及艾塞那肽的一种每周一次剂型被批准用于治疗2型糖尿病患者。另一种胰高血糖素样肽-1受体激动剂司美格鲁肽正在接受美国食品药品监督管理局的审查，通过渗透微型泵给药的艾塞那肽也在接受审查。
Zotero 插件